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Abstract
Background: A natural glycoprotein usually exists as a spectrum
of glycosylated forms, where each protein molecule may be
associated with an array of oligosaccharide structures. The overall
range of glycoforms can have a variety of different biophysical and
biochemical properties, although details of structure^function
relationships are poorly understood, because of the microheter-
ogeneity of biological samples. Hence, there is clearly a need for
synthetic methods that give access to natural and unnatural
homogeneously glycosylated proteins. The synthesis of novel
glycoproteins through the selective reaction of glycosyl iodoace-
tamides with the thiol groups of cysteine residues, placed by site-
directed mutagenesis at desired glycosylation sites has been
developed. This provides a general method for the synthesis of
homogeneously glycosylated proteins that carry saccharide side
chains at natural or unnatural glycosylation sites. Here, we have
shown that the approach can be applied to the glycoprotein
hormone erythropoietin, an important therapeutic glycoprotein
with three sites of N-glycosylation that are essential for in vivo
biological activity.
Results : Wild-type recombinant erythropoietin and three
mutants in which glycosylation site asparagine residues had been
changed to cysteines (His10-WThEPO, His10-Asn24Cys, His10-
Asn38Cys, His10-Asn83CyshEPO) were overexpressed and pur-
ified in yields of 13 mg l31 from Escherichia coli. Chemical
glycosylation with glycosyl-L-N-iodoacetamides could be mon-
itored by electrospray MS. Both in the wild-type and in the mutant
proteins, the potential side reaction of the other four cysteine
residues (all involved in disulfide bonds) were not observed. Yield
of glycosylation was generally about 50% and purification of
glycosylated protein from non-glycosylated protein was readily
carried out using lectin affinity chromatography. Dynamic light
scattering analysis of the purified glycoproteins suggested that the
glycoforms produced were monomeric and folded identically to
the wild-type protein.
Conclusions: Erythropoietin expressed in E. coli bearing specific
AsnCCys mutations at natural glycosylation sites can be
glycosylated using L-N-glycosyl iodoacetamides even in the
presence of two disulfide bonds. The findings provide the basis
for further elaboration of the glycan structures and development
of this general methodology for the synthesis of semi-synthetic
glycoproteins. ß 2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Erythropoietin (EPO) is a glycoprotein hormone synthe-
sized in humans by the foetal liver and adult kidney. As a
mature glycoprotein, EPO regulates the production of er-
ythrocytes operating under a classical feedback mechanism
whereby elevated serum oxygen levels result in lower
EPO expression and low oxygen concentrations result in
increased EPO production [1^3]. In cases of chronic
renal failure, the kidneys are no longer capable of pro-
ducing EPO resulting in anemia, a condition which can
be corrected by intravenous administration of recombi-
nant human EPO (rhEPO), successfully negating the
need of regular blood transfusions for patients on dialysis.
It is therefore not surprising that rhEPO is among the
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most successful recombinant therapeutics on the market
[4].
EPO is a glycoprotein which exists as a heterogeneous
mixture of glycoforms. With as many as 58 di¡erent N-
linked glycans associated with a single sample [5], it has
proved di⁄cult to evaluate the e¡ects of glycosylation on
the structure and function of rhEPO raising many issues
relating to its use as a therapeutic with regards to quality
control, antigenicity and patenting. Many groups have
reported on the importance of glycosylation for the in
vivo biological activity of EPO [6^16]. Using methods
such as expression of wild-type and mutant EPO in mam-
malian cell lines, expression in glycosylation ‘de¢cient’
mammalian cell lines, and expression of EPO in Escheri-
chia coli, it has become possible to gain some insight as to
which glycans are important and why. To summarise the
¢ndings brie£y, the O-linked glycan at serine 138 was
found not to be required for biological activity in vitro
or in vivo, although it may serve to stabilise the folded
structure. More importantly, the N-linked glycans at as-
paragines 24, 38 and 83 are essential for in vivo activity,
increasing circulatory half-life through sialylation of tetra-
antennary oligosaccharides (which comprise the major N-
linked oligosaccharides on EPO) and allowing for correct
folding and normal secretion (secretion of EPO is reduced
to 10% in the absence of N-linked glycosylation), presum-
ably through interaction with chaperones in the endoplas-
mic reticulum [17].
Although EPO is a perfect example of a therapeutic
whose remarkable activity has intrigued biologists and
chemists alike, employing all the techniques available to
the glycobiologist in attempts to evaluate the precise or
relative importance of the N-linked glycans, it also dem-
onstrates the wider need for the development of methods
which would further allow us to explore the role of glyco-
sylation at the molecular level. As protein glycosylation is
not under direct genetic control, the preparation of speci¢c
glycoforms may bene¢t from a chemical or chemoenzy-
matic in vitro approach.
Chemical approaches to the synthesis of homogeneous
glycoproteins are complicated by two major factors: (1)
Chemical synthesis of large proteins (s 100 amino acids
(aa)) is still a formidable task as automated solid phase
peptide synthesis (SPPS) becomes ine⁄cient for peptides
s 50 residues [18], a problem which may be soon over-
come through novel developments in convergent protein
synthesis such as native ligation and expressed protein
ligation [18^24]. (2) Although new developments in carbo-
hydrate chemistry have made the synthesis of large struc-
turally de¢ned glycans possible, oligosaccharide synthesis
is still far from routine and its union with peptide syn-
thesis less routine still, presenting a considerable challenge
for the synthesis of glycopeptides containing as few as 20
amino acid residues which has been met by only a handful
of groups [25^30].
While new synthetic methods for glycoprotein assembly
continue to bear fruit, so does the synthesis of neoglyco-
peptides, or glycopeptide mimetics [31^33]. Neoglycopep-
tides and proteins have proven themselves to be invaluable
tools for glycobiology for understanding carbohydrate^
lectin interactions, proximal peptide^sugar conformational
requirements and for the synthesis of immunostimulating
glycoconjugates [34^36]. Continuing research in the group
has been directed towards the development of a glycosyl-
ation strategy ¢rst reported by Flitsch and co-workers us-
ing a site-directed mutagenesis glycosylation approach
[37^39] whereby free thiol groups of cysteine residues are
selectively modi¢ed using glycosyl iodoacetamides (Fig. 1).
The attractiveness of such an approach has been exploited
by other groups [40,41] (Fig. 1), most recently by Jones
and co-workers for the synthesis of robust and active gly-
coforms of the protease subtilisin (which is not naturally
glycosylated) [42], in this case using alkane methylthiosul-
fonates as the thiol selective electrophiles, thus generating
disul¢de linkages.
It has been our aim to undertake a systematic study of
the e¡ects of speci¢c glycans on the structure and activity
of rhEPO through AsnCCys mutations at the natural N-
linked glycosylation sites (N24, N38, and N83), followed
by site speci¢c glycosylation after refolding, utilising the
Fig. 1. Selective glycosylating reagents for cysteine side chains [37,41,42].
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strategy outlined in Fig. 2. This is considerably more chal-
lenging than in previous reports where thiol modi¢cation
takes place on proteins bearing fortuitously free cysteine
residues or on otherwise cysteine-free proteins which are
not naturally glycosylated. Thus, EPO was chosen as a
more realistic candidate for in vitro chemical glycosylation
because it contains additional cysteine residues involved in
disul¢de linkages.
2. Results and discussion
2.1. Protein expression
His10-WT EPO and cysteine muteins (N24C, N38C and
N83C) were overexpressed and puri¢ed from E. coli (strain
B834(DE3)) using the pET16b expression system as pre-
viously described by Boissel and co-workers [17] and es-
sentially according to the manufacturer’s instructions.
EPO samples expressed in E. coli were found to be ex-
pressed in a highly aggregated, oxidised form with formed
disul¢des. In the case of the cysteine mutants the proteins
were found to be covalently linked to glutathione so prior
to oxidative refolding the samples were reduced.
The decahistidine sequence that had been added to the
N-terminus of the recombinant protein allowed facile one
step puri¢cation by metal chelation a⁄nity chromatogra-
phy. Surprisingly, rather than the expected single protein
product, two proteins of similar molecular weight were
shown to co-elute from the Ni2 a⁄nity column (Fig. 3,
upper panels). This was also shown to be the case when
the protein was overexpressed in E. coli strains
BL21(DE3) and BL21(DE3)PlysS (data not shown).
Both protein species were detected by a monoclonal anti-
body raised against an N-terminal epitope of rhEPO.
MALDI-TOF analysis of the product mixture showed
that the lower band of 21 097 Da was most likely to be
His10-C38hEPO (the calculated molecular weight for
His10-C38hEPO is 20 906 Da) and the upper was shown
to be carrying an extending sequence. Analysis of the
pET16b multiple cloning site indicated that the extending
sequence could arise from an ine⁄cient stop (TGA) co-
don, an occurrence also reported by MacBeath and co-
workers when working with pET vectors [43,44]. The pres-
ence of a unique restriction site (StuI) 26 base pairs from
the 3P end of the EPO gene allowed us to introduce a short
synthetic oligonucleotide duplex, comprising a new stop
codon (TAA) and optimised codons for protein expression
in E. coli, using cassette mutagenesis (Table 1). Expression
of the modi¢ed sequence and puri¢cation of His10-EPO’s
from B834(DE3) cells a¡orded His10-WT and cysteine mu-
tein EPO in yields of 13 mg l31 with no undesirable ex-
tending sequences (Fig. 3, lower panels).
2.2. Protein analysis by mass spectrometry
In order to monitor our glycosylation reactions, it was
realised that the accuracy of mass spectrometer data had
to be improved. The MALDI-TOF spectra were very help-
ful qualitatively but only provided masses within 50^150
Da of the calculated molecular weights. Increased resolu-
tion was achieved using on-line LC-ESI-MS of reduced
protein samples. Protein samples were initially eluted
from the Ni2 a⁄nity column as highly aggregated species
(veri¢ed by non-reducing SDS^PAGE). Reduction with
10^50 mM dithiothreitol (DTT) or Tris^carboxyethyl
phosphine (TCEP) prior to LC-MS a¡orded monomeric
and highly charged species (Fig. 4), from which good MS
data and accurate masses (within 5^20 Da) could be ob-
tained for our protein samples (Table 2).
2.3. Oxidative refolding of protein
Protein samples were reduced after Ni2 a⁄nity puri¢-
cation, dialysed against 6 M guanidinium hydrochloride,
50 mM Tris^HCl; pH 8.0 under a nitrogen atmosphere,
diluted 1:50 (to approximately 1 WM) and oxidatively re-
folded by dialysis against 2% N-lauroyl sarcosine, 50 mM
Tris^HCl, pH 8.0, 40 WM CuSO4 [17]. Refolded protein
was then concentrated by passing the dilute protein solu-
Fig. 2. Cysteine mutants are refolded to expose a single free thiol and the free thiol groups are glycosylated with glycosyl iodoacetamides (shown sche-
matically in red).
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tion, via a syringe ¢lter, over 1.5 ml (bed volume) of Ni2
charged a⁄nity resin. Comparable refolding e⁄ciency was
also obtained when the protein samples were refolded us-
ing an alternative, ‘pulsed’, refolding strategy [45] prior to
concentration.
2.4. Protein glycosylation
After puri¢cation, refolding and immobilisation of EPO
samples on Ni2 charged a⁄nity resin protein samples
were eluted from the a⁄nity resin in 200 mM imidazole
in 6 M guanidinium hydrochloride and the glycosyl iodo-
acetamide (1, Fig. 1) was added to a ¢nal concentration of
10 mM. The reaction was monitored by removing aliquots
of the reaction mixture and determining the extent of re-
action by LC-ESI-MS (Fig. 5). The reactions did not pro-
ceed to completion even with initial concentrations of
GlcNAc iodoacetamide as high as 50 mM, but the addi-
tion of only a single GlcNAc residue was observed in all
cases.
It should be noted that the addition of imidazole was
important for achieving selective glycosylation. When re-
folded protein samples were concentrated by precipitation
and redissolved in reaction bu¡er free of imidazole the
reaction was found to be less selective for cysteine thiols
and glycosylation was also observed on the N-terminal
polypeptide sequence up to residue Ile6, possibly on the
N-terminus or on the decahistidine sequence. This was
determined using 2-nitro-5-thiocyanato-benzoic acid
(NTCBA) mediated cleavage of the peptide backbone
[46] followed by analysis using electrospray mass spec-
trometry (data not shown).
Fig. 3. Expression of the native EPO sequence in pET16b (upper panel, left) a¡orded two gene products, one carrying a 2 kDa extending sequence
(upper panel, right). Expression of EPO, modi¢ed with a new stop codon results in a single species (lower panels).
Table 1
Oligonucleotides for cassette mutagenesis
Oligonucleotide Orientation Sequence 5PC3P
EPOCOPT 1 sense CC TGC CTG ACC GGT GAC CGT TAA TGA G
EPOCOPT 2 antisense GA TCC TCA TTA ACG GTC ACC GGT ACG GCA GG
The TAA stop codon precedes the original TGA stop codon.
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Interestingly, under denaturing conditions, His10-
C38EPO was most e⁄ciently glycosylated (s 60%), fol-
lowed by His10-C83EPO and then His10-C24EPO (30%
as determined by ESI-MS). Protein glycosylation was
less e⁄cient when the protein samples were eluted from
the a⁄nity column and glycosylated after refolding.
2.5. Neoglycoprotein puri¢cation
Neoglycoproteins were readily puri¢ed from unglycosy-
lated material using wheatgerm agglutinin lectin from Tri-
ticum avesticum immobilized on 4% beaded agarose. The
reaction mixture was dialysed against lectin binding bu¡er
(3 M guanidine^HCl, 50 mM Tris^HCl; pH 7.5, 1 M
NaCl, 1 mM MnCl2, 1 mM CaCl2) and applied to the
column. After washing unbound protein from the column,
the glycoprotein was eluted using lectin binding bu¡er
containing 500 mM N-acetyl glucosamine (GlcNAc) and
glycoprotein fractions were monitored using electrospray
LC-MS (Fig. 5).
2.6. Peptide mapping
After con¢rmation by mass spectrometry that only one
Fig. 4. ESI-MS charge spectra of aggregated (oxidised) His10-C38EPO (upper panel) and reduced (50 mM DTT) His10-C38hEPO (lower panel).
Table 2
Calculated and observed masses of reduced WThEPO, C24, C38 and
C83 cysteine mutants
His10-EPO species Calculated mass (Da) Observed mass (Da)
Mono-isotopic Average
WT 20 903.8 20 916.9 20 912.6
C24 20 892.8 20 905.9 20 902.1
C38 20 892.8 20 905.9 20 902.8
C83 20 892.8 20 905.9 20 898.0
Mass di¡erences between calculated and observed masses are likely to
have resulted from di¡erences in instrument calibration.
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Fig. 5. (a) ESI-MS of reduced protein samples can provide accurate masses such that addition of sulfhydryl modifying reagents can be observed.
(b) Optimised glycosylation conditions (plus imidazole in the reaction bu¡er) result in increased glycosylation of His10-C38hEPO with almost no His-tag
modi¢cation. (c) Lectin a⁄nity puri¢ed His10-C83(GlcNAc)hEPO.
Fig. 6. Digestion of immobilised WThEPO with chymotrypsin resulted in two major fragments: 321 M to 15Y (upper left) and 321 M to 49Y (lower
left). Digestion of the glycosylated C38 mutant with chymotrypsin also gave these fragments; less 11 Da for AsnCCys mutation. In this case (right)
the larger 8 kDa fragment is also glycosylated.
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carbohydrate residue had been attached to each protein it
was important to rigorously establish the site of chemical
glycosylation on the EPO polypeptide chain. In this con-
text it was encouraging to ¢nd that wild-type EPO expres-
sion in the same vectors as the cysteine mutants (i.e. di¡er-
ing only by the single Asn to Cys mutation) did not react
with iodoacetamide 1 as con¢rmed by mass spectrometry
(data not shown).
For more detailed analysis, several selective hydrolysis
protocols, both chemical and enzymatic, were investigated
in order to establish the glycosylation site by peptide map-
ping.
Although it was possible to separate glycosylated from
unglycosylated protein using lectin a⁄nity chromatogra-
phy, the whole reaction mixture (glycosylated and ungly-
cosylated protein) was analysed, since unglycosylated ma-
terial functioned as a useful internal calibrant for mass
spectrometry measurements. Initially, well-established pro-
teolysis protocols for tryptic digests were studied. Thus,
peptides were dissolved at concentrations of approxi-
mately 60 WM in 3 M guanidinium hydrochloride and
digested with trypsin or chymotrypsin for 1^16 h. Analysis
was complicated by the fact that proteolytic cleavage sites
were clustered about the regions of interest a¡ording small
polar peptide fragments which failed to bind reverse phase
columns and eluted with the bu¡er salts (for C24 and C38
mutants), diminishing their ability to be detected by the
mass spectrometer.
Since the areas of interest were close to the N-terminal
decahistidine sequence for mutants C24 and C38, reduced
glycoprotein samples were immobilised on charged Ni2
a⁄nity resin and subjected to solutions of protease on
resin. After washing, soluble protein fragments were eluted
from the column with imidazole. Chymotrypsin was found
to be most e¡ective, reproducibly a¡ording two soluble
fragments with molecular weights of approximately 4.3
kDa and 8 kDa (Fig. 6). These soluble fragments could
then be puri¢ed and subjected to further proteolytic cleav-
age by trypsin or V8 protease in volatile bu¡ers (50 mM
NaHCO3, pH 8.0) compatible with LC-ESI-MS. Further
analysis of these soluble peptides indicated that glycosyl-
ation had occurred on the desired fragment (between res-
idues 21 and 45 as determined by tryptic digest; Fig. 7,
and between residues 24 and 43 as determined by V8 pro-
teolysis; Fig. 8). The glucosamine residue could not be
completely assigned to the C38 (for His10-C38hEPO) or
C24 (for His10-C24hEPO) as the observed peptide frag-
ments also housed the cysteine residues of the native
Fig. 7. MS-MS veri¢ed that the correct fragment was glycosylated. The [EAENITTG29CAEH33CSLN E38CITVPDTK]3 ions corresponding to the un-
glycosylated (indicated in blue) and glycosylated (red) tryptic fragments were analysed. Although the sugar peptide linkage was not stable to the se-
quencing conditions (collision induced fragmentation of parent ion 979.76), the appearance of the characteristic molecular ion (N-acetyl hexosamines) at
204.08 indicated that it was in fact present. MS-MS sequencing also showed that both peptides contained similar daughter ions after collision induced
dissociation and the peptide sequences were identical.
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C29^C33 disul¢de bond. Cleavage with V8 protease re-
peatedly failed to cleave the peptide backbone at the glu-
tamate residues within this short peptide sequence (Fig. 8).
Isotopic analysis of the molecular ions in (Fig. 7) showed
that this 3+ ion corresponds to a mass which was two
mass units smaller than calculated indicating that a disul-
¢de bond was present in this short peptide. Encouragingly,
glycosylation was never observed on C7 or C161 (the cys-
teine residues which form a disul¢de bond linking the N-
and C-termini of the native folded structure). This was
also true for C24hEPO. In the case of the C83hEPO mu-
tant, the glycosylation site was on a larger peptide frag-
ment, near no other cysteine residues, allowing the glyco-
sylated fragment to be observed more readily (calculated
molecular weight = 5868, observed molecular weight =
5866, Fig. 9) and allowing unambiguous assignment of
the C83 glycosylation site.
As an alternative protein cleavage method, the chemical
reagent NTCBA (2-nitro-5-thiocyano-benzoic acid) was
explored, which is known to selectively cleave peptide
Fig. 8. Glycosylated His10-C38EPO fragments produced by V8 proteolysis of the soluble 8 kDa chymotryptic fragment (see Fig. 6, right). Peaks 3 and
4 correspond to glycosylated 1 and 2 respectively. The smaller equidistant peaks are +23 Na adducts.
Fig. 9. Tryptic digest of glycosylated His10-C83hEPO, shows glycosylation on C83.
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bonds adjacent to free cysteine residues. NTCBA treat-
ment of the reduced wild-type EPO protein indeed pro-
duced fragments corresponding to cleavage at cysteine res-
idues 7, 29, 33 and 161, and similar results were observed
for cysteine mutants (Table 3). As would be predicted,
glycosylation at speci¢c sites of the cysteine mutants ap-
peared to prevent NTCBA cleavage of the peptide back-
bone. Unfortunately it was not possible to observe the
expected larger fragment of molecular weight = 14 412.3
Da, corresponding to glycosylation on C38 (frag-
ment = C33-(C38(GlcNAc))-A160) because of apparent
elimination of the carbohydrate from the glycosylated pep-
tide fragment during NTCBA treatment resulting in a pep-
tide with mass = 14 249 Da (163 Da smaller than pre-
dicted). Glycosylation was therefore monitored by
proteolytic rather than chemical (NTCBA) cleavage.
However, NTCBA cleavage proved to be useful for de-
termining the nature of the side product of the glycosyla-
tion reaction that was initially observed when treatment
with iodoacetamide 1 was performed in the absence of
imidazole. After NTCBA cleavage a glycosylated N-termi-
nal fragment up to residue Ile6 was identi¢ed as contain-
ing the second glycosylation site. Since this glycosylated
peptide fragment was stable to NCTBA cleavage condi-
tions, this suggests that this second glycosylation site was
due to a nucleophilic residue other than the thiol of cys-
teine.
2.7. E¡ects of glycosylation on EPO stability
Recombinant EPO expressed in E. coli easily aggregates
and for nearly a decade had evaded complete structural
analysis using standard biophysical techniques. Only re-
cently have the crystal structures been solved of the
EPO/EPO receptor complex [3] and NMR structure of
E. coli derived EPO containing hydrophilic amino acid
substitutions and additions [47].
Dynamic light scattering (DLS) [48] was considered
ideal for initial studies of how glycosylation a¡ects
hEPO structure, as it was relatively insensitive to the
high salt concentrations needed to solubilise EPO. Using
a DynaPro-801 light scattering unit we could measure
light scattered at an angle of 90‡ from a protein solution
as it passes through an avalanche photodiode into an au-
tocorrelator. Measuring the changes in light scattering as a
function of time one can obtain the translational di¡usion
coe⁄cient (DT) and ultimately the hydrodynamic radius
(RH) using the Stokes^Einstein equation:
RH  kBT=6ZRDT
Where kB is the Boltzmann constant, T is the absolute
temperature and R is the solvent viscosity. Using DLS
we hoped to provide further evidence that our refolded
glycoproteins were monomeric and provide some insight
to their stability relative to unmodi¢ed protein. Non-re-
ducing SDS^PAGE analysis had indicated that our re-
folded proteins were monomeric and not aggregated
(data not shown). These results were validated by DLS
(Fig. 10). By measuring light scattering as a function of
increasing concentration of guanidine hydrochloride the
resulting ‘unfolding curve’ showed a smooth transition
to a ‘random coil’ state of the protein with a mid-point
of about 2 M guanidine hydrochloride for both the His10-
WThEPO and the puri¢ed glycosylated His10-C83hEPO.
The data compare well with previous ¢ndings [16] where
circular dichroism spectroscopy was employed to deter-
mine a mid-point for unfolding at 1.75 M guanidine hy-
Table 3
Calculated and observed masses for the peptide fragments resulting from NTCBA cleavage of His10-C38hEPO
Fragment masses for His10-C38hEPO NTCBA fragments
Gly(-21)-Ile6 Cys7-Gly28 Cys29-His32 Cys33-Glu37 Cys38-Ala160 Cys161-End
Calculated 3186.5 2535.8 483.5 589.6 13 593.8 731.8
Observed 3186.0 2534.5 ^ n/o 13592.5 n/o
Masses under 500 Da were not observed as they lay out with the acquisition range (500^2000 Da). n/o = not observed.
Fig. 10. Dynamic light scattering in the presence of increasing concen-
trations of guanidinium hydrochloride show little di¡erence in stability
of His10-C83(GlcNAc)hEPO relative to His10-WThEPO.
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drochloride for Chinese hamster ovary (CHO) cell derived
(glycosylated) EPO and 1.2 M for E. coli derived EPO.
Our results suggest that there is no signi¢cant destabilisa-
tion resulting from the introduction of the novel glyco-
amino acid.
3. Signi¢cance
The N-glycosylation of proteins is an important co-
translational modi¢cation greatly implicated in protein
folding, stability and function [18,34,49]. As a result of
not being under direct genetic control, new methods for
the synthesis of glycoproteins and neoglycoproteins should
prove valuable. Through site-directed mutagenesis it was
possible to successfully introduce single AsnCCys muta-
tions at the natural N-linked glycosylation sites of eryth-
ropoietin. An N-terminal decahistidine tag allowed e⁄-
cient expression and puri¢cation of protein samples. The
mutants were refolded according to literature procedures
with no signi¢cant loss of material. The refolded protein
samples were then treated with an excess of the glycosyl
iodoacetamide 1, which a¡orded only singly glycosylated
products. Rigorous ESI-MS analysis of the resulting gly-
coproteins showed glycosylation on the desired region of
the protein. Lectin a⁄nity chromatography was then em-
ployed to separate glycosylated protein from unglycosy-
lated protein and the stability of puri¢ed glycoforms could
be evaluated using dynamic light scattering. This showed
that the proximal N-acetyl glucosamine residue did not
considerably a¡ect the stability of the muteins relative to
the wild-type erythropoietin. To our knowledge this is the
¢rst example where a natural glycosylation site has been
targeted for chemical glycosylation using the present meth-
odology. It is also the ¢rst report in which the method of
using engineered cysteine glycosylation sites has been used
in the presence of other cysteine side chains involved in
disul¢de linkages. The results suggest that the method of
cysteine mutagenesis combined with chemical glycosyla-
tion is an attractive and general method for generating
neoglycoproteins with structural properties very similar
to natural glycoproteins. This method also allows intro-
duction of larger and more structurally complex glycans
which will be the focus of future research.
4. Materials and methods
4.1. General experimental details
Genes encoding WThEPO and cysteine mutants [38] were in-
serted (NdeI/BamHI) into pET16b (Novagen). Proteins were ex-
pressed and puri¢ed from E. coli essentially according to the
manufacturer’s instructions and as described by Boissell and co-
workers. His-bind resin was from Novagen, All restriction endo-
nucleases and DNA modifying enzymes were obtained from New
England Biolabs and were used according to the suppliers in-
structions. Murine anti-human EPO monoclonal antibody was
obtained from Genzyme diagnostics. HRP-conjugated rabbit
IgG to mouse IgG was from DAKO. IPTG was from Europa.
Guanidine^HCl was obtained from Fluka and 6 M solutions
were ¢ltered through a 0.45 Wm ¢lter (from Millipore) prior to
use. All other routine laboratory reagents were from Sigma. Mass
spectrometry of protein samples and modi¢ed protein samples
was carried out on a Micro-Mass Platform ESI mass spectrom-
eter. ESI spectra were recorded at a cone voltage of 70 V. Data
was analysed using mass lynx v2.3 software. For on-line LC-MS,
HPLC was carried out on a Waters 2690 microbore separations
module connected to a Waters1 tuneable absorbance detector set
at 280 nm. Flow rate = 0.05 ml min31. Samples were puri¢ed
using a PHENOMENEX Jupiter, microbore, C4 (1U150 mm)
reverse phase HPLC column (to remove trace amounts of salt
and small molecules) coupled to ESI-MS. Solvents for HPLC
were ¢ltered before use. HPLC conditions : 10^100% acetonitrile
over 20 min, 100% acetonitrile (10 min) then 100^10% acetonitrile
over 10 min.
4.2. Optimisation of EPO expression by the incorporation of a new
C-terminal sequence
Oligonucleotides (Table 1) were prepared by Gibco BRL and
were obtained fully deprotected and desalted. Equimolar quanti-
ties of oligonucleotides EPOCOPT 1 and EPOCOPT 2 were
mixed and diluted to 200 Wl with sterile water (¢nal concentra-
tion = 19.1 WM). The mixture was then heated in a boiling water
bath for 5 min and allowed to cool to room temperature. The
synthetic duplex was then ligated into BamHI/StuI cut pET16b-
WThEPO. After positives were identi¢ed, genes encoding the
cysteine mutants were subcloned (NdeI/StuI) into this optimised
vector. All optimised constructs were fully sequenced.
4.3. Renaturation of His10-EPO samples
Ni2 a⁄nity puri¢ed protein samples (30^60 WM (determined
using an estimated extinction coe⁄cient of 22 430 M31 cm31))
were reduced with 10 mM DTT for 3 h at 37‡C to a¡ord a
pale orange/brown solution. The reducing agent was then re-
moved by dialysis against 6 M guanidine^HCl, 50 mM Tris^
HCl, pH 8 under nitrogen. The dialysis procedure was monitored
using Ellmans reagent: A 1.0 ml sample of the dialysis bu¡er was
treated with 10 Wl 0.1 M Ellman’s reagent and absorption at 412
nm was measured. Dialysis was complete when A412 nm = 0. The
resulting colourless solution was then diluted 1:50 (0.6^1.2 WM)
and dialysed overnight at 4‡C against refolding bu¡er (2% w/v N-
lauroyl sarcosine, 50 mM Tris^HCl; pH 8, 40 WM CuSO4) and
then against 2% w/v N-lauroyl sarcosine, 50 mM Tris^HCl, pH 8
for a further 5 h. The protein samples could then be concentrated
by loading (via a 0.45 Wm syringe ¢lter) onto a Ni2 a⁄nity
column (equilibrated with ¢ve column volumes of refolding bu¡-
er) and eluted with refolding bu¡er containing 500 mM imida-
zole. Yields for the refolding step were determined by absorption
at 280 nm and found to be in excess of 80%.
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4.4. LC-MS analysis of intact or unmodi¢ed WT, C24, C38 and
C83 EPO samples
Unmodi¢ed His10-WT and mutant EPO’s were analysed di-
rectly by LC-MS spectrometry after Ni2 a⁄nity chromatogra-
phy and reduction with 10^50 mM DTT at 37‡C for 0.5 h
(although LC-MS can be carried out on unreduced samples, un-
reduced samples gave very poor, often unresolvable charge spec-
tra).
4.5. General method for refolded protein glycosylation with
glycosyl iodoacetamides
Ni2 a⁄nity puri¢ed EPO samples (3.0 ml, 60 WM, approxi-
mately 3.7 mg) were reduced and refolded as previously de-
scribed. The dilute refolded protein was then passed through a
0.45 Wm syringe ¢lter (50.0 ml syringe) onto a column of charged
His-bind resin (1.0 ml bed volume). After the refolding bu¡er had
drained the immobilised protein was eluted (6 M guanidine^HCl,
50 mM Tris, pH 8, 400 mM imidazole, 2.5 ml) and the column
was washed with further 6 M guanidine^HCl, 50 mM Tris, pH 8
(2.5 ml). The protein solution (approximately 20 WM as measured
by UV) was then treated with the glycosyl iodoacetamide to a
¢nal concentration of 10 mM (500Uexcess). The reaction was
then mixed on a blood rotator for 24 h with the exclusion of
light. The reaction was monitored by the removal of 0.5 ml ali-
quots, which were precipitated using 10 volumes of 1:1 acetone/
methanol. Precipitation was completed by incubation on ice for
10 min and the precipitate was collected by centrifugation. The
precipitate was dissolved in 6 M guanidine^HCl, 50 mM Tris, pH
8 (20 Wl), reduced by the addition of DTT to a ¢nal concentration
of 10 mM and heating at 37‡C (0.5 h), and analysed using on-line
LC-MS as described previously. The reactions were complete
when no further protein modi¢cation was observed in the ESI-
MS spectrum.
4.6. General method for 2-nitro-5-thiocyanato-benzoic acid
(NTCBA) analysis of His10-WT and cysteine mutant EPO’s
Ni2 a⁄nity column puri¢ed protein samples (typically 200 Wl ;
50 WM, 200 Wg) were precipitated using 10 volumes of 1:1 ace-
tone/methanol as previously described and redissolved in 100 Wl
alkylation bu¡er (6 M guanidinium^hydrochloride, 0.5 M Tris^
HCl, pH 8, 20 mM EDTA). DTT was then added to a ¢nal
concentration of 10 mM and the samples were incubated at
37‡C for at least 3 h. NTCBA was then added to a ¢nal concen-
tration of 30 mM and the resulting yellow/orange solution was
allowed to stand at room temperature for 0.5 h. The solution was
acidi¢ed to pH 4 with 30% TCA (60 Wl) and the modi¢ed protein
was precipitated from the now colourless solution as above. The
precipitate was taken up in 50 Wl cleavage bu¡er (3^6 M guani-
dinium^hydrochloride, 50 mM Tris^HCl, pH 10) and incubated
at 37‡C for 16 h. The reaction mixture was then analysed directly
using LC-MS.
4.7. Tryptic digest analysis of EPO samples
50 Wl of denatured protein samples in (Ni2 a⁄nity column)
elution bu¡er at concentrations of typically 55 WM (1.2 mg ml31)
were diluted with 50 Wl dH2O, treated with 0.4 Wl of 15 mg ml31
trypsin (¢nal protein:trypsin ratio of 20:1) and the resulting so-
lution was incubated at 37‡C for 16 h. After 16 h the cleavage
was observed by LCMS.
4.8. Tryptic digest analysis of reduced EPO samples
As above, except that the EPO sample was reduced with DTT
to a ¢nal concentration of 10 mM for 0.5 h and then the reducing
agent was removed by precipitation of the protein sample prior to
incubation with trypsin.
4.9. Tryptic/chymotryptic digest analysis of reduced and
immobilised EPO samples
EPO samples were initially reduced with 10 mM DTT for 1 h
at room temperature and the protein was separated from the
reducing agent by protein precipitation as previously described.
The protein samples were then redissolved in 6 M guanidine^HCl
or the minimum volume of 3 M guanidine^HCl and loaded onto
a Ni2 charged His-bind column (0.5 ml column bed). Any un-
bound material was removed by washing with 4 column volumes
(2.0 ml) of 3 M guanidine^HCl, 50 mM Tris^HCl, pH 7.3. A
solution of chymotrypsin (0.1^1.0 mg ml31) in 3 M guanidine^
HCl, 50 mM Tris^HCl, pH 7.3 (3.0 ml) was applied to the col-
umn and 1.0 ml of this solution was allowed to drain from the
column. The column was then plugged and the immobilised pro-
tein samples were exposed to the protease solution for a further
1 h. The protease solution was then allowed to drain from the
column and the resin was washed with 3 M guanidine^HCl, 50
mM Tris^HCl, pH 8 (10.0 ml), 6 M guanidine (1.0 ml) and water
(2.0 ml). Hydrophilic fragments were eluted from the column
with 400 mM imidazole and 0.25 ml fractions were collected.
2.5 Wl of each fraction was spotted onto nitrocellulose membrane
for Western ‘dot-blotting’. Once dry the fractions were probed
for N-terminal fragments using monoclonal murine anti-human
EPO antibody. Positive fractions were lyophilised. The lyophi-
lised sampled were taken up in DCM (0.5 ml) to dissolve the
imidazole and the peptide fragments were collected by centrifu-
gation. The supernatant was discarded and the remaining materi-
al was dissolved in 10 Wl of 1:1 acetonitrile/water, 0.1% TFA for
LC-ESI-MS analysis or dissolved in 10 mM NH4HCO3 for fur-
ther proteolysis.
4.10. Lectin a⁄nity chromatography
Glycosylated His10-EPO samples were puri¢ed using wheat-
germ agglutinin lectin from T. avesticum immobilized on 4%
beaded agarose (1.0 ml packed column bed volume). The column
was initially equilibrated with lectin binding bu¡er (LBB): 3 M
guanidine^hydrochloride, 50 mM Tris^HCl, pH 7.5, 1 M NaCl,
1 mM MnCl2, 1 mM CaCl2. The sample to be puri¢ed was dialysed
CHBIOL 62 7-3-01 Cyaan Magenta Geel Zwart
Research Paper Novel homogeneous glycoforms of EPO D. Macmillan et al. 143
against LBB overnight at 4‡C (or precipitated with acetone/meth-
anol as previously described and then redissolved in LBB). This
solution was applied to the column using a syringe ¢tted with a
0.45 Wm ¢lter. The unbound material was eluted and the column
with 10 column volumes of LBB to remove unglycosylated pro-
tein. The glycoprotein was then eluted using the same bu¡er
containing 500 mM N-acetyl glucosamine. Fractions could then
be analysed by SDS^PAGE or ESI-MS after concentration.
4.11. Dynamic light scattering (DLS)
Protein samples were concentrated to approximately 2 mg ml31
using a centricon (3 kDa molecular weight cuto¡). The concen-
trated stock solution was then injected through a 0.1 Wm ¢lter
into the light scattering cell until the lower cell was full (approx-
imately 13 Wl). The remaining stock solution was split into 300 Wl
aliquots. Guanidine^hydrochloride was added to each aliquot to
form ¢nal concentrations of 0.25 M to 6 M in 0.25 M increments.
Each aliquot was subjected to DLS to obtain an ‘unfolding
curve’.
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